New injection for eczema not helped by other advanced treatments
Treatments studied
Part of Genetic & congenital, Immune system & allergy, Skin clinical trials.
This study tests a new injection called amlitelimab for teens and adults with moderate-to-severe eczema that hasn't gotten better with other advanced treatments like biologics or JAK inhibitor pills. It's given along with steroid creams to see if it can improve symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 12 years or older.
- You have had eczema for at least 1 year.
- You have tried a biologic medicine (like Dupixent) or a JAK inhibitor pill (like Rinvoq) for your eczema, and it didn't work well enough.
- Your eczema is moderate to severe (covering at least 10% of your body, with a certain severity score).
- You weigh at least 55 pounds (about 25 kilograms).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new injectable medicine (611) for teenagers with moderate to severe eczema that hasn't been helped enough by creams. It aims to see if the drug can safely reduce itching and skin symptoms.
This study tests a new investigational drug called DCY636 to see if it can help people with moderate to severe atopic dermatitis (eczema) that hasn't improved with topical creams. The trial starts with safety testing in healthy volunteers, then moves to people with active eczema.
This study tests an injectable medication called MG-K10 to treat moderate-to-severe atopic dermatitis (eczema) in teenagers aged 12–17. The medication may help reduce itching and skin inflammation if topical creams haven't worked well enough.
This study tests two new study medicines (PF-07275315 and PF-07264660) for people with moderate to severe eczema that hasn't responded well to other treatments, including biologics. The goal is to see if these medicines can help reduce itching and clear the skin.
This study tests an investigational shot (tralokinumab) plus a steroid cream for children with moderate-to-severe eczema that hasn't been controlled by creams alone. It aims to see if the combination is safe and works better than the cream alone.
This trial tests if a pill called upadacitinib (a JAK inhibitor) can help adults with moderate-to-severe atopic dermatitis (eczema) that didn't improve enough with dupilumab. You may be able to join if your eczema is still active despite using dupilumab for at least 4 months.
Hear when a new Dermatitis Atopic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.